We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+4.41%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$279M
AUM Growth
-$62.9M
(-18%)
Cap. Flow
-$59.8M
Cap. Flow
% of AUM
-21.41%
Top 10 Holdings %
Top 10 Hldgs %
47.37%
Holding
72
New
12
Increased
18
Reduced
11
Closed
26
Top Buys
| 1 |
Ascendis Pharma A/S
ASND
|
+$10.4M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$8.55M |
| 3 |
MRUS
Merus
MRUS
|
+$7.77M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$5.58M |
| 5 |
WHWK
Whitehawk Therapeutics
WHWK
|
+$5.02M |
Top Sells
| 1 |
Xenon Pharmaceuticals
XENE
|
+$20.6M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$15.4M |
| 3 |
ALLK
Allakos
ALLK
|
+$9M |
| 4 |
GH Research
GHRS
|
+$6.59M |
| 5 |
Aldeyra Therapeutics
ALDX
|
+$5.34M |
Sector Composition
| 1 | Healthcare | 92.01% |
| 2 | Financials | 1.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma A/S
ASND
$17.1B
| $25.6M | 9.16% |
190,000
+70,000
| +58% | +$10.4M |
|
|
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
| $15.4M | 5.51% |
325,000
+125,000
| +63% | +$4.92M |
|
3
Cogent Biosciences
COGT
$6.68B
| $14.6M | 5.23% |
1,700,000
+200,000
| +13% | +$1.74M |
|
4
Celldex Therapeutics
CLDX
$2.77B
| $13.5M | 4.85% |
350,000
+95,000
| +37% | +$4.14M |
|
|
RAPT
5
DELISTED
RAPT Therapeutics
RAPT
| $12.9M | 4.61% |
43,750
+12,500
| +40% | +$3.34M |
|
|
MRUS
6
DELISTED
Merus
MRUS
| $11.1M | 3.99% |
350,000
+275,000
| +367% | +$7.77M |
|
|
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $10.4M | 3.75% |
625,000
-100,000
| -14% | -$1.64M |
|
8
Viridian Therapeutics
VRDN
$1.99B
| $9.88M | 3.54% |
500,000
+150,000
| +43% | +$2.79M |
|
|
9
CALL
Iovance Biotherapeutics
IOVA
$2.23B
| $9.54M | 3.42% |
+500,000
| New | +$11M |
|
10
Rocket Pharmaceuticals
RCKT
$376M
| $9.28M | 3.32% |
425,000
+75,000
| +21% | +$2.05M |
|
11
Arvinas
ARVN
$517M
| $9.04M | 3.24% |
110,000
-40,000
| -27% | -$3.25M |
|
|
12
Sarepta Therapeutics
SRPT
$1.82B
| $9.01M | 3.23% |
+100,000
| New | +$8.55M |
|
|
BLU
13
PUT
DELISTED
BELLUS Health Inc.
BLU
| $7.17M | 2.57% |
+891,000
| New | +$5.91M |
|
14
Zentalis Pharmaceuticals
ZNTL
$364M
| $6.72M | 2.41% |
80,000
+15,000
| +23% | +$1.16M |
|
15
Syndax Pharmaceuticals
SNDX
$2.02B
| $6.57M | 2.35% |
300,000
-275,000
| -48% | -$5.08M |
|
16
Vaxcyte
PCVX
$8.12B
| $5.95M | 2.13% |
250,000
+90,000
| +56% | +$2.09M |
|
|
FOLD
17
DELISTED
Amicus Therapeutics
FOLD
| $5.78M | 2.07% |
500,000
+235,000
| +89% | +$2.62M |
|
|
SRRA
18
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $5.43M | 1.95% |
250,000
+50,000
| +25% | +$1.1M |
|
|
19
Alnylam Pharmaceuticals
ALNY
$35.7B
| $5.09M | 1.82% |
+30,000
| New | +$5.58M |
|
|
VRNA
20
DELISTED
Verona Pharma
VRNA
| $5.04M | 1.81% |
750,000
| – | – |
|
|
WHWK
21
Whitehawk Therapeutics
WHWK
$192M
| $4.83M | 1.73% |
+200,000
| New | +$5.02M |
|
22
Aclaris Therapeutics
ACRS
$793M
| $4.73M | 1.69% |
325,000
+50,000
| +18% | +$758K |
|
|
CMPS
23
Compass Pathways
CMPS
$1.67B
| $4.64M | 1.66% |
210,000
+110,000
| +110% | +$3.5M |
|
24
Relmada Therapeutics
RLMD
$550M
| $4.51M | 1.61% |
200,000
| – | – |
|
|
MRTX
25
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.4M | 1.58% |
30,000
-30,000
| -50% | -$4.66M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q4 2021 Portfolio in Review
As of Q4 2021, Ghost Tree Capital held 72 positions worth $279M, down 18% from $342M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Ghost Tree Capital withdrew a net $59.8M in Q4 2021, closing 26 positions and reducing 11 holdings. Its most notable exit was Iovance Biotherapeutics, an estimated $15.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 87% a quarter earlier, followed by Financials.
Against the trend, Ghost Tree Capital opened a new position in Sarepta Therapeutics worth $9.01M.
- Ghost Tree Capital's largest Q4 2021 buy was Sarepta Therapeutics: 100,000 shares worth $9.01M.
- Ghost Tree Capital added most to Ascendis Pharma A/S in Q4 2021, an estimated $10.4M increase.
- Ghost Tree Capital's biggest Q4 2021 reduction was Xenon Pharmaceuticals, cutting an estimated $20.6M.
- Ghost Tree Capital fully exited Iovance Biotherapeutics in Q4 2021, selling an estimated $15.4M.
- Ghost Tree Capital's ten largest holdings make up 47% of its $279M portfolio in Q4 2021.
- Ghost Tree Capital opened 12 new positions and closed 26 in Q4 2021.
- Ghost Tree Capital's portfolio value fell 18% quarter-over-quarter to $279M.
Based on Ghost Tree Capital's 13F filing for Q4 2021, filed 16 Feb 2022.